ATE233570T1 - Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten - Google Patents

Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten

Info

Publication number
ATE233570T1
ATE233570T1 AT96913814T AT96913814T ATE233570T1 AT E233570 T1 ATE233570 T1 AT E233570T1 AT 96913814 T AT96913814 T AT 96913814T AT 96913814 T AT96913814 T AT 96913814T AT E233570 T1 ATE233570 T1 AT E233570T1
Authority
AT
Austria
Prior art keywords
endothelin antagonist
antagonist
inhibitor factor
leukemia inhibitor
endothelin
Prior art date
Application number
AT96913814T
Other languages
English (en)
Inventor
Napoleone Ferrara
Kathleen King
Elizabeth A Luis
Jennie P Mather
Nicholas F Paoni
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE233570T1 publication Critical patent/ATE233570T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT96913814T 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten ATE233570T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24
PCT/US1996/005498 WO1996033740A1 (en) 1995-04-24 1996-04-17 Use of leukemia inhibitory factor and endothelin antagonists

Publications (1)

Publication Number Publication Date
ATE233570T1 true ATE233570T1 (de) 2003-03-15

Family

ID=23694642

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96913814T ATE233570T1 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
AT02016730T ATE313333T1 (de) 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02016730T ATE313333T1 (de) 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten

Country Status (12)

Country Link
EP (2) EP1287832B1 (de)
JP (1) JPH11504332A (de)
AT (2) ATE233570T1 (de)
AU (1) AU702375B2 (de)
CA (1) CA2214636C (de)
DE (2) DE69635630T2 (de)
DK (2) DK0830143T3 (de)
ES (1) ES2254564T3 (de)
IL (1) IL117998A (de)
MX (1) MX9707939A (de)
WO (1) WO1996033740A1 (de)
ZA (1) ZA963274B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001404A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for $i(in vitro) fertilization
EP1549198A4 (de) * 2002-09-30 2007-03-28 Univ Duke Thymusatrophi
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (de) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Den humanen leukaemieinhibierenden Faktor (LIF) erkennender Antikörper und Verwendung von LIF-Antikörpern bei der Behandlung von Krankheiten im Zusammenhang mit ungewollter Zellproliferation
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
AU702375B2 (en) 1999-02-18
CA2214636C (en) 2009-12-22
EP1287832A3 (de) 2003-04-16
EP0830143B1 (de) 2003-03-05
EP0830143A1 (de) 1998-03-25
DE69626510D1 (de) 2003-04-10
ZA963274B (en) 1997-10-24
WO1996033740A1 (en) 1996-10-31
MX9707939A (es) 1997-12-31
JPH11504332A (ja) 1999-04-20
DE69635630D1 (de) 2006-01-26
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
DK0830143T3 (da) 2003-06-16
EP1287832A2 (de) 2003-03-05
CA2214636A1 (en) 1996-10-31
IL117998A0 (en) 1996-08-04
ES2254564T3 (es) 2006-06-16
IL117998A (en) 2001-04-30
EP1287832B1 (de) 2005-12-21
ATE313333T1 (de) 2006-01-15
DE69626510T2 (de) 2003-12-11
AU5665896A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
ATE185483T1 (de) Antivirale nucleosidkombination
ATE381935T1 (de) Verwendung von triacetyluridin zur behandlung von mitochondrialen erkrankungen
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
TR200001040T2 (tr) Kaşıntıyı önleme etkisi için bileşiklerin yeni bir kullanımı
ATE202599T1 (de) Mit isoliertem empfindlichem x-syndrom verbundene dns-sequenzen
ATE88349T1 (de) Hyperimmunizierte milch gegen bluthochdruck.
DE69626510D1 (de) Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
DE58902899D1 (de) 2',3'-dideoxypurinnucleosid/purinnucleosid-phosphorylase-inhibitor kombinationstherapie und zusammensetzungen dafuer.
ATE235245T1 (de) Pharmaceutische komposition
TR199801988T2 (xx) Kalp yetmezli�inin endotelin antagonistleri ile tedavisi i�in y�ntem.
NO894008L (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
NO990450L (no) Behandling av sinnslidelser
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ATE307600T1 (de) Verwendung von mycobacterium vaccae zur therapie des chronischen müdigkeitssyndrom
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
IT8519042A0 (it) Impiego di chinoloni nel trattamento di malattie cardiache.!
NO960545D0 (no) Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin
EP0116628A4 (de) 1-acyl-3-pyridylmethylguanidine und deren verwendung als antihypertensiva.
FI952018A0 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskriptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
DK0869813T3 (da) Anvendelse af beta-interferoner til behandling af restenose
DK0661058T3 (da) Anvendelse af bradykininantagonister til behandling af virussygdomme
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
SE9403861D0 (sv) Novel medicinal use

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0830143

Country of ref document: EP

REN Ceased due to non-payment of the annual fee